Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
This is a single center Phase I clinical trial of FT536 administered intraperitoneally (IP) 3 times a week for one week for the treatment of recurrent gynecologic cancers. A short course of outpatient lymphodepleting chemotherapy is given prior to the first dose of FT536 to promote adoptive transfer.
Gynecologic Cancer|Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cavity Cancer
DRUG: FT536|DRUG: Fludarabine|DRUG: CY
Progression free survival (PFS), 1 year
Progression free survival (PFS), 6 months|Overall survival (OS), 6 months|Overall survival (OS), 1 year
This is a single center Phase I clinical trial of FT536 administered intraperitoneally (IP) 3 times a week for one week for the treatment of recurrent gynecologic cancers. A short course of outpatient lymphodepleting chemotherapy is given prior to the first dose of FT536 to promote adoptive transfer.